¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º j7 D\O  
pJ5Sxgv{;  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ uIvE~<  
r#pC0Yj!3  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) .r?-O{2t  
]f q.r  
1. ICAM-1 JQ8wL _C>  
mPxph>o  
2. interleukin 12(IL-12) .~6p/fHX  
dg 4 QA_"  
3. tumor infiltrating lymphocyte \qqt/  
fG5U' Vw  
4. TCR/CD3 complex gX34'<Z  
aQaO.K2  
5. hematopoietin receptor family F"3PP ~  
R1FBH:Iu  
6. individual idiotype(IdI) ;X! sTs  
w7 ]@QTC  
7. integrin ;K0kQ<y-Y  
V 3-5:z  
8. colony-stimulatory factor (CSF) n9Z| 69W6>  
Dm[4`p@IY\  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 2* 5Z| 3aX  
WLEjRx  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? )G0a72  
<5A(rDij  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ mh!;W=|/"  
/v E>*x  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠi!<,8e=  
"EQ-`b=I4  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ h84}lxT ^]  
7^h?<X\  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) |Z<NM#1  
a 1Qg&s<  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ Aq}]{gfQ1  
c.Pyt  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) %zyO}  
C+$dm)M/q  
3. immunoglobulin superfamily (IgSF) #vYdP#nWb  
l njaHol0  
4. selectin [>Kkj;*  
^$Dpdz I  
5. anti-idiotypic antibody (¦ÁId) MVK='  
WaQ Cq0Enj  
6. major histocompatibility complex(MHC) ]L%qfy4  
aH e/MucK  
7. immunotolerance i=@.u=:  
|f&)@fUI  
8. biological reponse modifier(BRM) /pZLt)=P  
i2/:' i  
9. immune reponse gene (Ir gene) /cUcfe#X  
mdR:XuRD"t  
10. reshaped antibody (or reconstituted antibody) &i4*tE3],  
~mx me6"v  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© *<#jr  
W~k"`g7uu  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ ;(fDR8  
A!No:?S  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? I.A7H'j  
}BS.OK?  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ ao#{N=mn  
-z./6dQ  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? fDhV *LqW  
%+ YLe-\?  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ rlmzbIu I9  
u;p{&\ (]  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? b26#0;i  
mufi >}  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ :jB~rhZ~  
j+"i$ln+s  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ Q{T6t;eH  
&[ $qA  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? t=o0 #jo  
z %{Z  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ losm<  
[74HUw>  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: >UvLeS2h:y  
!|;^  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: UjxEbk5>^  
m/RX~,T*v&  
ÃâÒßѧ ".A+'pJ  
b9Jah  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© huFT_z_;;  
6t/nM  
1. CD8 _L 5<  
&HBqweI  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) 2u9O +]EP  
Agt6G\ n  
3. immunoglobulin fold(Ig fold) q-kMqnQ  
mOgsO  
4. cadherin (Ca-dependent cell adhesion moleculers) +Tz Z   
zY_xJ"/9  
5. idiotype-anti-idiotypic antibody immune network theory  mG4$  
aDEz |>q  
6. HLA class II antigen xuBXOr4"P  
.x\fPjB   
7. complementarity-determining region (CDR) MO}J  
4CAV)  
8. perforin(or pore-forming protein ,PFP) YDh6XD<Z  
~DY5`jV  
9. high affinity IL-2 receptor hLF+_{\C|  
'2)c;/-E  
10. artificial active immunization 4cZig\mE;  
ttQX3rmF01  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© rb8c^u#r  
MV8Lk/zd?A  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ^Ej4^d  
iV+'p->/  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 n =SY66  
e|Ip7`  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ oh%kuO T[  
?Q$LIoR  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ Eu%19s; u  
31BN ?q  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ [>`[1;aX  
t<`h(RczHI  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? 7lP3\7wD@9  
OBF3)L]  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ R<r"jOd]  
M~&|-Hm  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ ]>utLi5dX  
e"jA#Y #  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ >v4k_JX  
Bjg 21b w^  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ + n1jP<[<N  
0 O{Y Vk`  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© mwuFXu/  
|pIA9/~Z  
1. immunoglobulin gene rearrangement Ru%: z>Y  
JOj\#!\>k0  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) q.(p.uD  
T;-Zl[H  
3. flow cytometry(FCM) tVx.J'"Y  
Q9K+k*?{N  
4. carrier effect FswMEf-|  
fgxsC7P$  
5. positive selection of T lymphocytes in thymus c%.f|/.k  
>l$vu-k)~4  
6. mouse TH1(Th1) and TH2(Th2) subsets }@'xEx  
<$liWAGX\  
7. perforin (pore-forming protein ,PFP) XEqg%f  
{nQ}t }B  
8. ADCC(antibody-dependent cell-mediated cytotoxicity)  =erA.u  
)Jx!VJ^Y  
9. SH-2(src-homology region 2) l,/q# )5[  
'Rfvr7G/?  
10. Ab2¦Â (internal image) _lQ+J=J$.R  
.<Z7 K @  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© xsRMF&8L  
w8%yX$<  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? ^JtGT  
v>3ctP {  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? Tu_dkif'  
"!)8bTW  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠu2<:mu[|P  
nVG\*#*]|  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ z@y* jT  
=Ak>2  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠMbnV5b:X  
?p5RSt  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) BHj]w*Ov  
NtTLvO6  
ÃâÒßѧרҵ£º P[P!WLr""  
tzpGKhrk6  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ 8zj 09T[  
&s/aJgJhp  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 4)j<(5  
3UC8iq*  
´«È¾²¡Ñ§×¨Òµ£º BpP\C!:^  
1rPeh{SZ  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ ip5s'S~  
/HzhgMV3  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ zm8m J2s  
UjKHGsDi4  
Ïû»¯×¨Òµ£º )%j)*Ymz;  
XVv7W5/q]  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ &\p :VF.  
Olxb`x  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? M.OWw#?p:_  
NZlJ_[\$C  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ Gj)Qw 6  
:&:>sd(QD  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© p>}N9v;Bo  
)d.7xY7!  
1. Fas(CD95)/FasL t#pY2!/T3  
b&_p"8)_  
2. common chain of cytokine receptor Mvcl9  
L0_=R;.<  
3 . TCR/CD3 complex mMj Vbeh[  
',&MYm\  
4. negaive selection of thymocytes [&`>&u@MK  
X 1'Ze,34  
5. artificial active immune ih;TQ!c+b  
&GZR-/  
6. anti-idiotypic /nmfp&@  
%4 -pw|':  
7. IgSF #62ww-E~  
7> ]C2!  
8. Integrin ^}[ N4  
2bC%P})m  
9. chemokine *Xnq1_K}  
VsMNi#?  
10. B7/CD28 mT9\%5d3  
`&6]P:_qp  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© b>(l F%M  
24Tw1'mW  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ atAA[~  
'[E_7$d  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ vJ' 93 h  
4>HGwk@+8  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ =>J#_Pprn  
|Wgab5D>V  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ KAzRFX),  
K7Vr$,p  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ lq5E?B  
fpi6pcof  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ FHC7\#p/9Z  
'W*F[U*&HP  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© m t^1[  
u2Obb`p S  
1. B7/CD28 3"n8B6  
Z#O3s:`  
2. Th1 subset `ahXn  
wp*1HnWj8Y  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© do,X{\  
'1 $({{R  
4. antibody affinity maturation  (I.`bR  
5XHkRcESZ  
5. AP-1 k]iS3+nD  
+GS=zNw#  
6. single chain variable fragment£¨ScFv£© ($W 5fbu  
W V U9NmvE  
7. NK cell receptor J.l%H U  
K;y\ &'E  
8. Zinkernagel-Doherty phenomenon 2A|6o*s"  
eHe /w9`$R  
9. Ig fold %#a%Luq  
9A(K_d-!H  
10. CD40/CD40L |lwN!KVQ,  
:t^})%  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© F4%[R)  
:,,y63-f4  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ Qu_T&  
HPKyAcS\  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ nn:pf1  
:q <%wLs  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ ]#.&f]6l  
FF~4y>R7u  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ vP NZFi-(  
[frD L)  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 86F+N_>Z  
 7`@?3?  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ 2{Iz  
_ D}b  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ !bQ &n  
vXQmEIm  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© f+Li'?  
RmV/wY  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© 1|w:xG^  
8z8SwWS?  
1.Co-stimulators (or co-stimulating molecules) [<a%\:c m4  
>/kG5]zxY  
2.NK-kB B2qq C-hw?  
:gaeb8`t  
3.Immunoglobulin superfamily @<yc . >  
H6S vU  
4.antigen-presenting cell (APC) U]EuDNkO{  
)TG0m= *  
5.death domain B5H&DqWzr  
q.sQ Z]ty9  
6.CCR and CXCR ~2DV{dyj  
y&=19 A#  
7.Lectin (or mitogen) *([)X2A@+  
(Cd{#j<  
8.Clusters of differentiation, CD) Il`k]XM  
z<vO#  
9.B7 family 9f%y)[ \  
S}Y|s]6  
10.Cytotoxic T lymphocyte, CTL) 4'hcHdL9   
B"Kce"!  
11.IL-15 and IL-15 receptor (IL-15R) po2[uJ  
rbuL@= S@*  
12.MHC restriction ZWhmO=b!  
V52C,]qQH  
13.Affinity-chromatography fDEu%fUYZ  
]v\egfW,W  
14.Cyctosprin A, CsA CL'Xip')T  
XZdr`$zf  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) [+MX$y  
mV*/zWh_  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 5+/b$mHZX  
P&%eIgAOL  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 waWKpk1Wo  
zIm_7\e  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ D@\;@( |  
uJam $V  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ E_D ^O  
\9(- /rE  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 2Jo~m_  
>'}=.3\  
ÃâÒßѧרҵ£º A6NxM8ybn+  
V@ _-H gg  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ hP1 l v7P  
"o{)X@YN]  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ G=Hf&l  
5`E`Kb+@  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ 4j@i%  
x9)aBB  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) -!|WZ   
C1T=O  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) l 70,Jo?78  
%0yS98']g  
1. ADCC(antibody dependent cell-mediated cytotoxicity) ;n} >C' :  
^KkRF" :  
2. »·æß¾úËØ(cyclosporin) {4: -0itG  
!6zyJc @01  
3. KIR(killer cell inhibitory receptor) Sk/#J!T8{  
hI|/>4<  
4. HLDA(human leucocyte differentiation antigen) G[3k  
IX<r5!  
5. Interleukin 18(IL-18) g/8.W  
[dj5 $l|  
6. ÕûºÏËØ(integrin) |1(rr%  
~n[b^b  
7. Fas/FasL %5JW< 9  
a`H\-G  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) FXx.$W  
PSTu/^  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) J3B6X8P'  
Bx(yu'g|a  
10. Th1/Th2 5x8'K7/4.  
ajn-KG!A  
11. »ùÒòÒßÃç(DNAÒßÃç) ;rd6ko  
24|  
12. chemokines and chemokine receptor [tUv*jw%  
XQ]`&w(  
13. ÃâÒßÄÍÊÜ tbq|,"  
U1l0Uke  
14. ¹²´Ì¼¤·Ö×Ó KNy`Lj)VPY  
R0%?:! F  
15. ËÀÍö½á¹¹Óò(death domain) ~32Pjk~  
><[| G9  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) KiQ(XNx  
0pD W _  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? z^r |3;  
J"-_{)0lD  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠa\=-D:  
[*Q-nZ/L  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î 5O&d3;p'  
Q uB+vL  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ lr WLN  
R*087X7 N|  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå W6vf=I@f  
+@0TMK,P  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ be7L="vZw  
m4@MxQm  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 3L>d!qD  
SE T-8f  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ RX'-99M  
QQFf5^  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ Z'Q*L?E8M  
& 1_U1  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»